Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
New data with pasritamig plus docetaxel support a recent pivotal start.
But biomarker enrichment and toxicity remain key for FX-909.
The month saw the first commissioner's priority voucher approval in oncology.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
